In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC patients. Here, CXCR4 is linked to hereditary clear cell renal cell carcinoma.